Health policy directly impacts cancer outcomes. States without Medicaid expansion show higher triple-negative breast cancer (TNBC) mortality. Conversely, states with expanded Medicaid have documented improvements in early-stage diagnosis rates and survival, highlighting a critical lever for reducing health disparities.
The cumulative time spent coordinating care, attending appointments, and managing side effects is a significant resource drain termed "time toxicity." It disproportionately harms patients with inflexible jobs, caregiving duties, or limited travel funds, directly worsening health disparities in cancer treatment.
Many patients, particularly from minority backgrounds, miss out on targeted therapies due to delayed or incomplete biomarker testing. Implementing universal reflex testing for all TNBC patients at diagnosis is a systemic solution that ensures guideline-concordant care and reduces disparities in access to novel treatments.
A common barrier to PD-L1 testing in metastatic TNBC is insufficient tissue from the biopsy. Clinicians should remember that tissue from the primary tumor is a viable alternative for analysis. This simple workaround can prevent missed opportunities for patients to receive targeted immunotherapy.
Patient adherence with new drugs like ADCs often hinges on managing side effects in the first two cycles. This period requires significant "hand-holding," proactive follow-ups, and empathy to manage the patient experience, ensure compliance, and maintain quality of life before treatment becomes routine.
To improve clinical trial enrollment and patient preparedness, clinicians should "plant the seed" about potential adjuvant therapies early. Discussing options for residual disease during the neoadjuvant phase, rather than after surgery, helps patients plan and avoids overwhelming them with new information at a critical juncture.